Nifty Pharma stocks
The Nifty Pharma tracks India's largest listed drug makers, many of which earn much of their sales from generic medicines sold abroad.
Close on 19 Nov 2026 · 20 member stocks (list as of 20 Nov 2026)
- 1M
- +10.8%
- 3M
- +7.4%
- 6M
- +14%
- YTD
- +24.9%
- 1Y
- +24.8%
- 3Y
- +79.5%
- 5Y
- +110.5%
- 10Y
- +166.6%
Price returns: index level only, dividends not included.
Today in the Nifty Pharma
Prices at 03:29 pm IST, 20 Nov11 up, 9 down
16 of 20 trade above their 200-day average.
None near a 52-week high.
"Near" = within 1% of the highest or lowest price of the last year. Price moves only, not advice.
Top gainers
- Abbott India+3.09%
- Torrent Pharmaceuticals+1.7%
- Glenmark Pharmaceuticals+1.51%
- Ajanta Pharma+1.46%
- Mankind Pharma+1.37%
Top losers
- IPCA Laboratories−1.13%
- Sun Pharmaceutical Industries−0.79%
- Dr Reddy's Laboratories−0.76%
- Wockhardt−0.57%
- Laurus Labs−0.49%
What's new in Nifty Pharma companies
Notable exchange filings, credit rating actions and fund raises of the last 30 days, newest first.
Strong Q2 with 13.8% sales growth and 22.5% margin, but full-year margins to stay flat as new MedTech and biotech businesses drag.
SourceGlenmark launched authorized generic Inlyta in the US targeting a $538.4m brand market.
SourceSuperb Q2 with 32% sales and 64% profit growth guides to sustained double-digit growth and major peptide-led capex.
SourceIndia Ratings upgraded Sai Life Sciences: IND AA; IND A1+ (was IND AA-; IND A1+)
India Ratings upgraded Sai Life to AA Stable on strong growth and margins despite Rs 1100-1300 cr capex.
SourceStrong 21% H1 growth with 28% margins and 15% full-year guidance plus Rs 1000 cr new capacity backs sustained double-digit profitable growth.
SourceStrong 13.8% Q2 revenue growth plus Occlutech MedTech buy offset by higher new-regime tax and Biotech losses cutting PAT.
SourceStrong Q2 (+23%) with H2 guided stronger and Bidar expansion ready supports ~20% revenue growth amid heavy capex.
SourceSoft Q2 with 5% sales spilling to Q3, but double-digit H2 growth, $500m new contracts and lower interest point to stronger earnings.
Source
Nifty Pharma in numbers
Worked out from the member companies' latest results and today's market value. Our own sums, so they can differ a little from the figures NSE publishes.
- P/E
- 41.5x
- Market value ÷ profit
- P/B
- 5.7x
- Market value ÷ book
- Dividend yield
- 0.5%
- Weighted by size
- Median ROE
- 16%
- Return on equity
- Sales growth
- +22.7%
- Median, vs a year ago
- Profit growth
- −0.2%
- Median, vs a year ago
Results for the Sep 2026 quarter
19 of 20 companies have reported. Profit grew at 9 and sales at 16 of them, against the same quarter a year earlier.
Largest members by market value
- Sun Pharmaceutical Industries20.3% of the total
- Divi's Laboratories13.7% of the total
- Torrent Pharmaceuticals8% of the total
- Laurus Labs5.9% of the total
- Zydus Lifesciences5.4% of the total
Total market value ₹ 22,18,476 Cr.. P/E covers the 20 members with a profit and a market value. Shares of the total are by full market value, not NSE's free-float weights.
Nifty Pharma against other indices
Each line starts at 100, so you can read who gained more over the same time.
- Nifty Pharma+25%
- Nifty 50−2.6%
Index levels only, dividends not included. Weekly closes beyond one year.
All 20 stocks
Changes to the Nifty Pharma
No changes since we began tracking this list on 20 Nov 2026. NSE reviews its indices twice a year, with changes usually taking effect at the end of March and September; they will show here.